Anti-PD-1 Monoclonal Antibodies Market Estimations (2025 - 2035)
The anti-PD-1 monoclonal antibodies market covers monoclonal antibodies that block the PD-1 immune checkpoint receptor, including pembrolizumab, nivolumab, cemiplimab, dostarlimab, retifanlimab and China-developed sintilimab, tislelizumab, camrelizumab and toripalimab, in intravenous and subcutaneous forms, for lung, melanoma, kidney, head and neck, gastrointestinal and other cancers, in metastatic and early-stage settings.
📄Report ID:2508
|
📊Format: Databook
|
📅Published: 18 November 2026
|
⚡Delivery: Immediate